aod9604 phase 2 trial results weight loss kg or percent Orforglipron: The Oral Non-Peptide GLP-1 Agonist AOD-9604 Vial — Lyophilized, HPLC

Rinderknecht E, Humbel RE

10 CDCVaccine administration: subcutaneous route (angle/site

Importantly, preclinical studies showed that weight reduction occurred particularly in abdominal adipose tissue, the visceral fat depot most strongly associated with metabolic health risks

Handle according to laboratory safety protocols and institutional research guidelines

Powder consistent (dry)

Sources: Neelakantan et al., Biochem Pharmacol 2018 | Dimet-Wiley et al., Sci Rep 2024 Security Profile & Chemical Identity Molecular specifications and preclinical safety data 5-Amino-1MQ Chemical Identity A small molecule derived from quinolinium salts, developed at the University of Texas (2017) 5-Amino-1MQ Tolerance & Status Safety data from preclinical studies (DIO mouse model) Published Preclinical Data 3 key studies published in Biochemical Pharmacology and Scientific Reports 35% Reduction of white adipose tissue in 11 days (20 mg/kg, 3 times/day) Physical Effects (11 days) + 40 % Improvement of grip strength in aged mice (22-24 months) Strength & Performance (aged mice) microbiome The combination of 5-Amino-1MQ + caloric restriction establishes a distinct gut microbial profile Protocol & Results Important Notice Search Only Not intended for human consumption